Viewing Study NCT06247995

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 2:16 PM
Ignite Modification Date: 2026-01-05 @ 6:35 PM
Study NCT ID: NCT06247995
Status: RECRUITING
Last Update Posted: 2025-11-06
First Post: 2024-01-17
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.
Sponsor: Novartis Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Breast Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None metastatic View
None Estrogen receptor View
None ER positive View
None HER2 negative View
None radioligant therapy View
None Theranostic View
None GRPR View
None neoB View